STIMNeuronetics, Inc.
This year, STIM has to prove it can turn its TMS reimbursement tailspin into a revenue tailwind — and the first test is the October 15 decision on broader coverage for Transcranial Magnetic Stimulation. If the payors greenlight expanded use, the stock could climb to $2.30, but a delay or rejection would send it back to $1.60. The next catalyst is the November 10 earnings report, where the company will try to show it’s not just surviving but starting to thrive — and the market will be watching closely to see if the 2027 profitability story is real or just a PR play.
The Read
Following its Q4 2025 earnings miss and subsequent valuation reset, STIM saw a median absolute move of ~24%.
The schedule
- Thu15Oct
Commercial payor updates regarding coverage for Transcranial Magnetic Stimulation (TMS) across broader indications, alongside potential shifts in Medicare reimbursement speeds under President Trump's administration.
- Tue15Dec
A dedicated investor event or extensive business update detailing the new management's long-term strategic plan, commercial realignments, and product pipeline.
- Tue9Feb
Q3 results will test the durability of any turnaround initiated in Q2. Investors will seek early commentary on fiscal 2027 guidance and a credible path to sustained GAAP profitability.
- Sun14Feb
Full-year 2026 results and the critical formal rollout of FY2027 guidance, setting the baseline for the company's normalized growth rate.
- Sun16May
The Q1 print often acts as a reality check on the Q4 optimism, assessing initial execution against the newly established FY27 guidance.
Past
- Thu10Sep
Following potential Q2 momentum, STIM must demonstrate sustained trading above the $1.00 minimum bid price to eliminate delisting risk.
- Tue11Aug
Actual outcome: Bull · $3.30 at outcome
Neuronetics delivered strong Q2 results, featuring revenue growth, a sharply narrower net loss, and positive adjusted EBITDA driven by the expansion of its Greenbrook clinic business. The stock surged well past the bull target as the market cheered these fundamental improvements, along with new commercial purchasing options for its NeuroStar systems and a constructive alignment framework established with its second-largest shareholder.
Q2 earnings will be a pivotal show-me quarter. The market is closely watching for a transition toward positive operating cash flow and potential management restructuring to drive the next phase of growth.
- Wed15Jul
Actual outcome: Bear · $1.62 at outcome
Neuronetics participated in an industry summit during the event window but provided no immediate update to address its urgent funding gap. The absence of a capital raise announcement, coupled with ongoing market concerns regarding the company's gross margin struggles, weighed on sentiment and drove a 12% decline in the stock by the outcome date.
Given a cash balance of $13.2M against a quarterly cash burn of roughly $9.6M, Neuronetics faces an urgent near-term funding gap. A capital raise is highly probable.
- Thu18Jun
Actual outcome: Bear · $1.20 at outcome
At the annual shareholder meeting, management provided a reassuring update on the NeuroStar growth strategy and addressed cash runway concerns by outlining a clear path to sustained growth. Although the immediate price reaction was relatively flat, this strategic clarity and improved financial outlook ultimately drove the stock significantly higher in the following weeks, easily surpassing the bull target.
Shareholder meeting focused on strategic growth amidst cash runway concerns.
- Tue17Mar
Actual outcome: Bear · $1.32 at outcome
Neuronetics reported an EPS of -$0.13, which merely met analyst estimates rather than providing the narrowing loss required to validate its aggressive growth narrative. With the stock price falling significantly below the $1.80 bear floor to $1.32, it is evident that the 2026 guidance or revenue growth failed to meet the high expectations for triple-digit expansion, leading to a sharp valuation reset.
